Abstract：
Formulations from nanotechnology platform promote therapeutic drug delivery and offer various advantages such as biocompatibility, non-inflammatory effects, high therapeutic output, biodegradability, non-toxicity, and biocompatibility in comparison with free drug delivery. Due to inherent shortcomings of conventional drug delivery to cancerous tissues, alternative nanotechnological-based approaches have been developed for such ailments. Ovarian cancer is the leading gynecological cancer with higher mortality rates due to its reoccurrence and late diagnosis. In recent years, the field of medical nanotechnology has witnessed significant progress in addressing existing problems and improving the diagnosis and therapy of various diseases including cancer. Nevertheless, the literature and current reviews on nanotechnology are mainly focused on its applications in other cancers or diseases. In this review, we focused on the nanoscale drug delivery systems for ovarian cancer targeted therapy and diagnosis, and different nanocarriers systems including dendrimers, nanoparticles, liposomes, nanocapsules, and nanomicelles for ovarian cancer have been discussed. In comparison to non-functionalized counterparts of nanoformulations, the therapeutic potential and preferential targeting of ovarian cancer through ligand functionalized nanoformulations\' development has been reviewed. Furthermore, numerous biomarkers such as prostatic, mucin 1, CA-125, apoptosis repeat baculoviral inhibitor-5, human epididymis protein-4, and e-cadherin have been identified and elucidated in this review for the assessment of ovarian cancer. Nanomaterial biosensor-based tumor markers and their various types for ovarian cancer diagnosis are explained in this article. In association, different nanocarrier approaches for the ovarian cancer therapy have also been underpinned. To ensure ovarian cancer control and efficient detection, there is an urgent need for faster and less costly medical tools in the arena of oncology.
摘要：
纳米技术平台的配方促进治疗药物递送，并提供各种优势，如生物相容性，非炎性效应,高治疗输出，生物降解性，无毒性，与自由给药相比，生物相容性。由于常规药物递送至癌组织的固有缺点,针对此类疾病，已经开发了基于纳米技术的替代方法。卵巢癌是主要的妇科癌症，由于其复发和晚期诊断，死亡率较高。近年来,医学纳米技术领域在解决现有问题和改善包括癌症在内的各种疾病的诊断和治疗方面取得了重大进展。然而，有关纳米技术的文献和当前综述主要集中在其在其他癌症或疾病中的应用。在这次审查中,我们专注于卵巢癌靶向治疗和诊断的纳米药物递送系统，和不同的纳米载体系统，包括树枝状聚合物，纳米粒子，脂质体，纳米胶囊，和卵巢癌的纳米胶束已经被讨论过。与纳米制剂的非功能化对应物相比，综述了通过配体功能化纳米制剂对卵巢癌的治疗潜力和优先靶向的研究进展。此外，许多生物标志物，如前列腺，粘蛋白1，CA-125，凋亡重复杆状病毒抑制剂-5，人附睾蛋白-4和e-cadherin已被鉴定并阐明，用于评估卵巢癌。本文介绍了基于纳米材料生物传感器的肿瘤标志物及其用于卵巢癌诊断的各种类型。在协会中,卵巢癌治疗的不同纳米载体方法也得到了支持。为了确保卵巢癌的控制和高效检测，在肿瘤学领域，迫切需要更快，成本更低的医疗工具。
